Abionyx Pharma: to benefit from a 1ME grant from Bpifrance

(CercleFinance.com) - Abionyx Pharma announces an innovation grant of nearly 1 million euros from Bpifrance.
This aid is intended to support the CER-001 drug candidate, dedicated to the treatment of a severe indication in ophthalmology.

This aid will contribute to the financing of studies on the CER-001 drug candidate, and will be reimbursable at 0% interest on condition of success from the last quarter of 2026, until the first quarter of 2031.

Abionyx Pharma notes that the preclinical studies conducted to date have been a success, and would like to thank Bpifrance for its long-standing support.

Copyright (c) 2024 CercleFinance.com. All rights reserved.